Ampio Announces Successful Pre-IND Meeting with the Ophthalmology Division of the FDA on Optina for the treatment of DME
From Ampio Pharmaceuticals, Inc. — 8/2/2012
Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing drugs for the treatment of inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction today announced that a pre-IND meeting with the FDA's ophthalmology division of the Center for Drug Evaluation and Research (CDER) took place on July 31st 2012 seeking guidance for a clinical trial path for Optina(TM). A summary of the meeting is as follows:
The meeting followed a letter from the FDA providing guidance for the path of approval of Optina in the USA.
The FDA agreed to Ampio's proposed indication for Optina(TM) as a drug for the treatment of Diabetic Macular Edema (DME) in adults.
The FDA agreed that the approval process through the 505(b)2 pathway is acceptable.
The FDA raised no safety or CMC concerns.
The FDA agreed that no additional non-clinical studies are necessary and that guidance for the dose and inclusion/exclusion criteria for this larger trial may be drawn from the recently completed successful Canadian trial.
The proposed study, agreed by the FDA to be conducted by Ampio, will be based on similar end points as the intraocular injectable drug, Lucentis.
Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, noted: "We are now able to launch a larger study using visual acuity rather than Optical Coherence Tomography (OCT) as the measure of efficacy and we are able to adjust the dosage to body mass index (BMI) to achieve the optimal benefit. We are pleased that the injectable drug Lucentis(TM) is likely to be approved and made available to the underserved DME patients. We believe Optina may provide additional advantages to these patients, as Optina is administered orally and is based on a very low dose of a previously approved drug, danazol. Extensive clinical experience with the drug has allowed the FDA to permit Ampio to use the 505(b)2 path for drug registration. The 505(b)2 is a significantly shorter and less expensive path than those of new chemical entities. There is an obvious advantage to an oral drug vs. one that requires injection directly into the eye. Complications such as eye infection, increased intra ocular pressure (IOP) and local eye irritation reported in the Lucentis studies are NOT a concern for Optina."
Michael Macaluso, Ampio's CEO, reflected on the achievement of this latest milestone, "One year ago we selected three (3) drugs from our extensive pipeline and set as our goal the advancement of each drug through carefully managed clinical paths into late stage pivotal trials that are within our means to finance, are relatively short in duration and in full compliance with FDA guidance. These preparatory clinical trials took place in Europe (Zertane), Australia (Ampion) and Canada (Optina). With this latest meeting with the FDA, we have met our interim goal. We now have two drugs poised for pivotal trials (Zertane) and Ampion and Optina is approved for a 505 (b) 2 pathway in the USA."